Navigation Links
UCSD research team identifies novel anticancer drug from the sea
Date:2/11/2008

A collaborative team of researchers spearheaded by Dennis Carson M.D., professor of medicine and director of the Rebecca and John Moores UCSD Cancer Center at the University of California, San Diego (UCSD) has identified a potent new anti-cancer drug isolated from a toxic blue-green algae found in the South Pacific. The properties of somocystinamide A (ScA) are described in a paper that will be published online in Proceedings of the National Academy of Science the week of February 11 -15.

We are excited because we have discovered a structurally unique and highly potent cancer-fighting compound, said Dwayne G. Stupack, associate professor of pathology at the Moores UCSD Cancer Center. We envision it will be perfect for emerging technology, particularly nanotechnology, which is being developed to target cancerous tumors without toxic side effects.

The ScA compound was found in the cyanobacteria L. Majuscula, also known as mermaids hair, gathered off the coast of Fiji in the South Pacific by the laboratory of William Gerwick at Scripps Institution of Oceanography. A diverse team of researchers from UCSDs Cancer Center, School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences, and Scripps worked to identify, screen and test marine compounds in vitro and in vivo. They found that ScA inhibits neovascularization, the formation of blood vessels that feed tumors, and also had a direct impact on tumor cell proliferation.

The compound isnt toxic to the cyanobacteria itself, but activates a death pathway, present in our cells, said Stupack. When the cells of the blood vessels that feed tumors become activated and proliferate, they become especially sensitive to this agent.

Gerwick noted that if a normal-sized swimming pool full of cancer cells were treated with ScA, it would take only three milligrams about the weight of a grain of rice to kill all of the cancer cells.

Wolf Wrasidlo, Ph.D., senior project scientist at the Moores UCSD Cancer Center and first author of the work, added that the unique structure of this compound lends itself very well to nanotechnology, because it incorporates spontaneously into molecule-sized nanoparticles, important for the kind of highly targeted, combination therapy being developed to treat cancer. The structure is also simple enough that the scientists can reproduce it.

ScA is the first, and most potent compound weve identified so far, Stupack said, adding that it wont be the last, as the Scripps team has identified more than 250 unique compounds from L. Majuscula alone. But we dont yet know how abundant ScA is, or if its feasible to harvest, so it is important that we have been able to produce this natural product in the lab.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
2. Oregon researchers discover a mechanism leading to cleft palate
3. Penn childhood obesity researchers panelists at AAAS Town Hall Event
4. Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
5. Psoriasis Cure Now Applauds Record Government Psoriasis Research Funding
6. Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming Walk for a Cure
7. ECNP launches research grant for young scientists
8. European blood researchers receive award to pursue research opportunities in US
9. P\S\L Group appoints Paul Barnes as Group President P\S\L Research
10. Worlds best analysts compete to win Edelman Prize in operations research and analytics
11. Thousands of Womens Basketball Referees to Wear Pink Whistles February 8-17; Calling For a Cure Program to Raise Funds for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSD research team identifies novel anticancer drug from the sea
(Date:8/16/2017)... ... August 16, 2017 , ... ... affiliations and de novo development, today announced Cumberland Skin Surgery and Dermatology ... Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, provides comprehensive ...
(Date:8/16/2017)... ... 2017 , ... Paul Vitenas, MD, FACS , is honored to announce ... list identifies the nation’s top physicians, in a variety of specialties. This marks the ... of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of ... every reprocessing cycle, both between patient procedures and before storage, is a requisite ... as important to the prevention of disease transmission and nosocomial infection as cleaning ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology: